-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, M+kyRZ4YgIV2w485PRMuXRc3XgrhmtOdgeaooV0gzRu7+u5vlDGH4z/gjhH2fF9S hxe3Wcu6FXQFKCRFDJoISA== 0000950172-05-000071.txt : 20050106 0000950172-05-000071.hdr.sgml : 20050106 20050106161003 ACCESSION NUMBER: 0000950172-05-000071 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20041231 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20050106 DATE AS OF CHANGE: 20050106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 05515865 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 8-K 1 bos322830.htm 8K Form



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):    December 31, 2004


REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)


New York 000-19034 133444607
(State or other jurisdiction
of incorporation)		 (Commission
File Number) 		(IRS Employer
Identification No.)


777 Old Saw Mill River Road, Tarrytown, New York   10591-6707
(Address of principal executive offices)      (Zip Code)


(914) 347-7000
(Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))




Item 1.01 Entry into a Material Definitive Agreement

  On December 31, 2004, the Company and Aventis Pharmaceuticals, Inc. entered into a First Amendment (the “First Amendment”) to their Collaboration Agreement dated as of September 5, 2003 (the “Collaboration Agreement”). The First Amendment amended the requirements for the $25 million milestone 1 payment referred to in Schedule 2 of the Collaboration Agreement. The Company has met these amended requirements and thus earned this $25 million milestone in December 2004. No other changes were made to the terms of the Collaboration Agreement.





                Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    REGENERON PHARMACEUTICALS, INC.


Dated: January 6, 2005   By: /s/ Stuart Kolinski
       
        Stuart Kolinski
Vice President and General Counsel
-----END PRIVACY-ENHANCED MESSAGE-----